Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20355)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | GR50 | GRmax | GR_AOC | GEC50 | GRinf | GR Hill Coefficient | GR r2 | pval_GR |
|---|---|---|---|---|---|---|---|---|---|
| AU565 | LY3023414 | 0.003983539 | -0.4704 | 0.7921 | 0.8999 | -1.0000 | 0.2027 | 0.8707 | 7.87e-12 |
| HCC1395 | Ulixertinib | 1.871580782 | 0.1659 | 0.2498 | 4.1054 | -0.2114 | 0.4489 | 0.7753 | 7.87e-09 |
| HCC70 | AZD5363 | 0.0251705169742 | -0.2793 | 0.6653 | 0.5821 | -0.6722 | 0.2713 | 0.8708 | 7.80986386673e-12 |
| MDA-MB-157 | Alvocidib | 0.152222738 | -0.8658 | 0.2879 | 0.2794 | -1.0000 | 1.8087 | 0.9385 | 7.77e-16 |
| MDA-MB-468 | BMS-265246 | 0.129448207 | -0.1039 | 0.5150 | 7.7796 | -1.0000 | 0.2682 | 0.8711 | 7.57e-12 |
| SUM149PT | AZD2014 | 1.870533874 | 0.3557 | 0.3916 | 1000.0000 | -0.6285 | 0.1296 | 0.8137 | 7.57e-10 |
| HCC1419 | RO-3306 | 8.899414267 | 0.2237 | 0.0089 | 11.0863 | -1.0000 | 5.0000 | 0.7309 | 7.48e-08 |
| HCC70 | LY3023414 | 0.00246998519581 | -0.7413 | 0.7828 | 0.7825 | -1.0000 | 0.1908 | 0.6120 | 7.2607777184e-06 |
| BT-549 | LY3023414 | 0.000704789836999 | -0.4244 | 0.7781 | 1.5836 | -0.9316 | 0.1363 | 0.8143 | 7.2423111952e-10 |
| MCF 10A | SHP099 | 13.33532157 | 0.6599 | 0.0155 | 20.0345 | -1.0000 | 2.6990 | 0.8458 | 7.1e-11 |
| Hs 578T | SHP099 | 222.1051901 | 0.5953 | 0.1451 | 1000.0000 | -0.2087 | 0.2319 | 0.7318 | 7.17e-08 |
| HCC1937 | AZD5363 | 12.85319785 | 0.4773 | 0.3596 | 0.0112 | 0.4671 | 0.3863 | 0.5345 | 7.07e-05 |
| MDA-MB-361 | GSK2334470 | 0.050377803 | -0.4513 | 0.5704 | 2.8790 | -1.0000 | 0.2716 | 0.7322 | 7.05e-08 |
| MDA-MB-231 | AZD6738 | 8.82761747838 | 0.3448 | -0.0384 | 12.4996 | -0.9998 | 3.1583 | 0.8459 | 7.04556413211e-11 |
| CAL-120 | BMS-265246 | 2.125230074 | 0.3446 | 0.3401 | 1000.0000 | -0.9133 | 0.1688 | 0.8479 | 6e-11 |
| HCC38 | Ribociclib | 0.517768611 | 0.2321 | 0.4237 | 305.2273 | -1.0000 | 0.1722 | 0.8460 | 6.98e-11 |
| HCC1937 | BMS-265246 | 0.000340758 | -0.0634 | 0.9143 | 0.0005 | -0.0734 | 0.4108 | 0.8462 | 6.89e-11 |
| CAMA-1 | AZD6738 | 8.908669378 | 0.2804 | -0.0237 | 11.1124 | -1.0000 | 4.9704 | 0.6787 | 6.86e-07 |
| T47D | BMS-265246 | 0.014946978 | -0.0154 | 0.6421 | 2.6347 | -0.7862 | 0.1827 | 0.8936 | 6.85e-13 |
| SUM1315MO2 | Ulixertinib | 5.524882323 | 0.1115 | 0.1198 | 15.1090 | -1.0000 | 1.0920 | 0.7778 | 6.82e-09 |
| MDA-MB-468 | AZD6738 | 10.56189758 | 0.4777 | 0.0335 | 23.3227 | -0.9834 | 1.3728 | 0.7330 | 6.79e-08 |
| MDA-MB-134-VI | THZ1 | 0.006632255 | -0.4554 | 0.6285 | 0.0190 | -0.5267 | 0.6824 | 0.8938 | 6.71e-13 |
| T47D | GSK2334470 | 0.455522213 | 0.1531 | 0.3958 | 0.9464 | -0.1424 | 0.3428 | 0.9385 | 6.66e-16 |
| MCF 10A | AZD5363 | inf | 0.6025 | 0.2092 | 0.0802 | 0.5789 | 0.3665 | 0.9389 | 6.66e-16 |
| CAL-85-1 | THZ531 | 0.06303794 | -0.2628 | 0.4242 | 0.3186 | -0.8133 | 0.5961 | 0.6795 | 6.65e-07 |